Tag: Cecile Kerloeguen

Poster-Disease-modifying Therapy

Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies

Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...

Read More